Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats
Authors:
- Mei-Shu LinMLMei-Shu Lin
- Chang-Her TsaiCTChang-Her Tsai
- Nen-Chung ChangNCNen-Chung Chang
Open Access
- 1 December 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 291 (6) , H2705-H2713
Abstract
We have demonstrated that myocardial ATP-sensitive potassium (KATP) channels are implicated in the development of cardiac hypertrophy in hyperlipidemic rabbits. We investigated the effect of pravastatin on development of ventricular hypertrophy in male normolipidemic Wistar rats with two-kidney, one-clip (2K1C) hypertension and whether the attenuated hypertrophic effect was via activation of KATPchannels. Twenty-four hours after the left renal artery was clipped, rats were treated with one of the following therapies for 8 wk: vehicle, nicorandil (an agonist of KATPchannels), pravastatin, glibenclamide (an antagonist of KATPchannels), hydralazine, nicorandil plus glibenclamide, or pravastatin plus glibenclamide. Systolic blood pressure, relative left ventricular (LV) weight, and cardiomyocyte sizes significantly increased in vehicle-treated 2K1C rats compared with those in sham-operated rats. Treatment with either nicorandil or pravastatin significantly attenuated LV hypertrophy/body weight compared with the vehicle, which was further confirmed by downregulation of LV atrial natriuretic peptide mRNA. Nicorandil-induced effects were abolished by administering glibenclamide. Similarly, pravastatin-induced beneficial effects were reversed by the addition of glibenclamide, implicating KATPchannels as the relevant target. A dissociation between the effects of blood pressure and cardiac structure was noted because pravastatin and hydralazine reduced arterial pressure similarly. These results suggest a crucial role of cardiac KATPchannel system in the development of ventricular hypertrophy in the 2K1C hypertensive rats. Pravastatin is endowed with cardiac antihypertrophic properties probably through activation of KATPchannels, independent of lipid and hemodynamic changes.Keywords
This publication has 46 references indexed in Scilit:
- Effect of pravastatin on left ventricular mass by activation of myocardial KATP channels in hypercholesterolemic rabbitsAtherosclerosis, 2004
- Long-Acting Ca 2+ Blockers Prevent Myocardial Remodeling Induced by Chronic NO Inhibition in RatsHypertension, 2003
- Roles of Oxidative Stress and AT 1 Receptors in Renal Hemodynamics and Oxygenation in the Postclipped 2K,1C KidneyHypertension, 2003
- Differential Effects of Sarcolemmal and Mitochondrial KATP Channels Activated by 17β-Estradiol on Reperfusion Arrhythmias and Infarct Sizes in Canine HeartsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJournal of Clinical Investigation, 2001
- Extracellular Signal-regulated Kinase Plays an Essential Role in Hypertrophic Agonists, Endothelin-1 and Phenylephrine-induced Cardiomyocyte HypertrophyJournal of Biological Chemistry, 2000
- Endothelin System–Dependent Cardiac Remodeling in Renovascular HypertensionHypertension, 1999
- Sulfonylurea derivatives in cardiovascular research and in cardiovascular patientsCardiovascular Research, 1997
- Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990